Optimization of imidazo[4,5- b ]pyridine-based kinase inhibitors: Identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8721-8734

  Bavetsias, Vassilios ^a   Crumpler, Simon ^a   Sun, Chongbo ^a   Avery, Sian ^a   Atrash, Butrus ^a   Faisal, Amir ^a   Moore, Andrew S ^a   Kosmopoulou, Magda ^a   Brown, Nathan ^a   Sheldrake, Peter W ^a   Bush, Katherine ^a   Henley, Alan ^a   Box, Gary ^a   Valenti, Melanie ^a   De Haven Brandon, Alexis ^a   Raynaud, Florence I ^a   Workman, Paul ^a   Eccles, Suzanne A ^a   Bayliss, Richard ^a   Linardopoulos, Spiros ^a   Blagg, Julian ^a   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 7 [4 (4 CHLOROBENZYL)PIPERAZIN 1 YL] 2 (1,3 DIMETHYL 1H PYRAZOL 4 YL) 3H IMIDAZO[4,5 B]PYRIDINE; AURORA KINASE INHIBITOR; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; RAT; REACTION OPTIMIZATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; MODELS, MOLECULAR; MUTATION; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PURINES; PYRAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867813052     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300952s     Document Type: Article

References (65)

1. Carmena, M; Earnshaw, W. C. The Cellular Geography of Aurora Kinases Nat. Rev. Mol. Cell Biol. 2003, 4, 842-854
2. Ducat, D.; Zheng, Y. Aurora Kinases in Spindle Assembly and Chromosome Segregation Exp. Cell Res. 2004, 301, 60-67
3. Marumoto, T.; Zhang, D.; Saya, H. Aurora-A, a Guardian of Poles Nat. Rev. Cancer 2005, 5, 42-50
4. Barr, A. R.; Gergely, F. Aurora-A: The Maker and Breaker of Spindle Poles J. Cell Sci. 2007, 120, 2987-2996
5. Bayliss, R; Sardon, T.; Vernos, I.; Conti, E. Structural Basis of Aurora-A Activation by TPX2 at the Mitotic Spindle Mol. Cell 2003, 12, 851-862
6. Giet, R.; Glover, D. M. Drosophila Aurora B Kinase Is Required for Histone H3 Phosphorylation and Condensin Recruitment During Chromosome Condensation and to Organise the Central Spindle During Cytokinesis J. Cell Biol. 2001, 152, 669-681
7. Gassmann, R.; Carvalho, A.; Henzing, A. J.; Ruchaud, S.; Hudson, D. F.; Honda, R.; Nigg, E. A.; Gerloff, D. L.; Earnshaw, W. C. Borealin: A Novel Chromosomal Passenger Required for Stability of the Bipolar Mitotic Spinde J. Cell Biol. 2004, 166, 179-191
8. Sessa, F.; Mapelli, M.; Ciferri, C.; Tarricone, C.; Areces, L. B.; Schneider, T. R.; Stukenberg, P. T.; Musacchio, A. Mechanism of Aurora B Activation by INCENP and Inhibition by Hesperadin Mol. Cell 2005, 18, 379-391
9. Bishop, J. D.; Schumacher, J. M. Phosphorylation of the Carboxyl Terminus of Inner Centromere Protein (INCENP) by Aurora B Kinase Stimulates Aurora B Kinase Activity J. Biol. Chem. 2002, 277, 27577-27580
10. Tanaka, T.; Kimura, M.; Matsunaga, K.; Fukada, D.; Mori, H.; Okano, Y. Centrosomal Kinase AIK1 Is Overexpressed in Invasive Ductal Carcinoma of the Breast Cancer Res. 1999, 59, 2041-2044
11. Bischoff, J. R.; Anderson, L.; Zhu, Y.; Mossie, K.; Ng, L.; Souza, B.; Schryver, B.; Flanagan, P.; Clairvoyant, F.; Ginther, C.; Chan, C. S. M.; Novotny, M.; Slamon, D. J.; Plowman, G. D. A Homologue of Drosophila Aurora Kinase is Oncogenic and Amplified in Human Colorectal Cancers EMBO J. 1998, 17, 3052-3065
12. Gritsko, T. M.; Coppola, D.; Paciga, J. E.; Yang, L.; Sun, M.; Shelley, S. A.; Fiorica, J. V.; Nicosia, S. V.; Cheng, J. Q. Activation and Overexpression of Centrosome Kinase BTAK/Aurora-A in Human Ovarian Cancer Clin. Cancer. Res. 2003, 9, 1420-1426
13. Reichardt, W.; Jung, V.; Brunner, C.; Klein, A.; Wemmert, S.; Romeike, B. F. M.; Zang, K. D.; Urbschat, S. The Putative Serine/Threonine Kinase Gene STK15 on Chromosome 20q13.2 is Amplified in Human Gliomas Oncol. Rep. 2003, 10, 1275-1279
14. Chieffi, P.; Troncone, G.; Caleo, A.; Libertini, S.; Linardopoulos, S.; Tramontano, D.; Portella, G. Aurora B Expression in Normal Testis and Seminonas J. Endocrinol. 2004, 181, 263-270
15. Araki, K.; Nozaki, K.; Ueba, T.; Tatsuka, M.; Hashimoto, N. High Expression of Aurora-B/Aurora and Ipl1I-like Midbody-Associated Protein (AIM-1) in Astrocytomas J. Neurooncol. 2004, 67, 53-64
16. Sorrentino, R.; Libertini, S.; Pallante, P. L.; Troncone, G.; Palombini, L.; Bavetsias, V.; Cernia, D. S.; Laccetti, P.; Linardopoulos, S.; Chieffi, P.; Fusco, A.; Portella, G. Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phenotype and is Required for Thyroid Carcinoma Cell Proliferation J. Clin. Endocrinol. Metab. 2005, 90, 928-935
17. Kimura, M.; Matsuda, Y.; Yoshioka, T.; Okano, Y. Cell Cycle-dependent Expression and Centrosome Localisation of a Third Human Aurora/Ipl1-related Protein Kinase, AIK3 J. Biol. Chem. 1999, 274, 7334-7340
18. Pollard, J. R.; Mortimore, M. Discovery and Development of Aurora kinase inhibitors as anticancer agents J. Med. Chem. 2009, 52, 2629-2651
19. Moore, A. S.; Blagg, J.; Linardopoulos, S.; Pearson, A. D. J. Aurora Kinase Inhibitors: Novel Small Molecules With Promising Activity in Acute Myeloid and Philadelphia- Positive Leukemias Leukemia 2010, 24, 671-678
20. Gautschi, O.; Heighway, J.; Mack, P. C.; Purnell, P. R.; Lara, P. N., Jr.; Gandara, D. R. Aurora Kinases as Anticancer Drug Targets Clin. Cancer Res. 2008, 14, 1639-1648
21. Ikezoe, T.; Yang, J.; Nishioka, C.; Tasaka, T.; Taniguchi, A.; Kuwayama, Y.; Komatsu, N.; Bandobashi, K.; Togitani, K.; Koeffler, H. P.; Taguchi, H. A Novel Treatment Strategy Targeting Aurora Kinases in Myelogenous Leukemia Mol. Cancer Ther. 2007, 6, 1851-1857
22. Ochi, T.; Fujiwara, H.; Suemori, K.; Azuma, T.; Yakushijin, Y.; Hato, T.; Kuzushima, K.; Yasukawa, M. Aurora-A Kinase: A Novel Target of Cellular Immunotherapy for Leukemia Blood 2009, 113, 66-74
23. Huang, X.-F.; Luo, S.-K.; Xu, J.; Li, J.; Xu, D.-R.; Wang, L.-H.; Yan, M.; Wang, X.-R.; Wan, X.-B.; Zheng, F.-M.; Zeng, Y.-X.; Liu, Q. Aurora Kinase inhibitory VX-680 Increases Bax/Bcl-2 Ratio and Induces Apoptosis in Aurora-A-High Acute Myeloid Leukemia Blood 2008, 111, 2854-2865
24. Walsby, E.; Walsh, V.; Pepper, C.; Burnett, A.; Mills, K. Effects of the Aurora Kinase Inhibitors AZD1152-HQPA and ZM447439 on Growth Arrest and Polyploidy in Acute Myeloid Leukemia Cell Lines and Primary Blasts Haematologica 2008, 93, 662-669
25. Green, M. R.; Woolery, J. E.; Mahadevan, D. Update on Aurora Kinase Targeted Therapeutics in Oncology Expert Opin. Drug Discovery 2011, 6, 291-307
26. Cheung, C. H. A.; Coumar, M. S.; Chang, J.-Y.; Hsieh, H.-P. Aurora Kinase Inhibitor Patents and Agents in Clinical Testing: An Update (2009-10) Expert Opin. Ther. Patents 2011, 21, 857-884
27. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M. C.; Miller, K. M. VX-680, a Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppresses Tumor Growth In Vivo Nat. Med. 2004, 10, 262-267
28. Mortlock, A. A.; Foote, K. M.; Heron, N. M.; Jung, F. H.; Pasquet, G.; Lohmann, J-J. M.; Warin, N.; Renaud, F.; De Savi, C.; Roberts, N. J.; Johnson, T.; Dousson, C. B.; Hill, G. B.; Perkins, D.; Hatter, G.; Wilkinson, R. W.; Wedge, S. R.; Heaton, S. P.; Odedra, R.; Keen, N. J.; Crafter, C.; Brown, E.; Thompson, K.; Brightwell, S.; Khatri, L.; Brady, M. C.; Kearney, S.; McKillop, D.; Rhead, S.; Parry, T.; Green, S. Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase J. Med. Chem. 2007, 50, 2213-2224
29. Fancelli, D.; Moll, J.; Varasi, M.; Bravo, R.; Artico, R.; Berta, D.; Bindi, S.; Cameron, A.; Candiani, I.; Cappella, P.; Carpinelli, P.; Croci, W.; Forte, B.; Giorgini, M. L.; Klapwijk, J.; Marsiglio, A.; Pesenti, E.; Rocchetti, M.; Roletto, F.; Severino, D.; Soncini, C.; Storici, P.; Tonani, R.; Zugnoni, P.; Vianello, P. 1,4,5,6-Tetrahydropyrrolo[3,4- c ]pyrazoles: Identification of a Potent Aurora Kinase Inhibitor With a Favorable Antitumor Kinase Inhibition Profile J. Med. Chem. 2006, 49, 7247-7251
30. Caprinelli., P.; Ceruti, R.; Giorgini, M. L.; Cappella, P.; Gianellini, L.; Croci, V.; Degrassi, A.; Texido, G.; Rocchetti, M.; Vianello, P.; Rusconi, L.; Storici, P.; Zugnoni, P.; Arrigoni, C.; Soncini, C.; Alli, C.; Patton, V.; Marsiglio, A.; Ballinari, D.; Pesenti, E.; Fancelli, D.; Moll, J. PHA-739358, a Potent Inhibitor of Aurora Kinases With a Selective Target Inhibition Profile Relevant to Cancer Mol. Cancer Ther. 2007, 6, 3158-3168
31. Payton, M.; Bush, T. L.; Chung, G.; Ziegler, B.; Eden, P.; McElroy, P.; Ross, S.; Cee, V. J.; Deak, H. L.; Hodous, B. L.; Nguyen, H. N.; Olivieri, P. R.; Romero, K.; Schenkel, L. B.; Bak, A.; Stanton, M.; Dussault, I.; Patel, V. F.; Geuns-Meyer, S.; Radinsky, R.; Kendall, R. L. Preclinical Evaluation of AMG900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines Cancer Res. 2010, 70, 9846-9854
32. Bavetsias, V.; Large, J. M.; Sun, C.; Bouloc, N.; Kosmopoulou, M.; Matteucci, M.; Wilsher, N. E.; Martins, V.; Reynisson, J.; Atrash, B.; Faisal, A.; Urban, F.; Valenti, M.; de Haven Brandon, A; Box, G.; Raynaud, F. I.; Workman, P.; Eccles, S. A.; Bayliss, R.; Blagg, J.; Linardopoulos, S.; McDonald, E. Imidazo[4,5- b ]pyridine Derivatives as Inhibitors of Aurora kinases: Lead Optimization Studies Toward the Identification of an Orally Bioavailable Preclinical Development Candidate J. Med. Chem. 2010, 53, 5213-5228
33. Yang, D.; Fokas, D.; Li, J.; Yu, L.; Baldino, C. M. A Versatile Method for the Synthesis of Benzimidazoles from o -Nitroanilines and Aldehydes in One Step via a Reductive Cyclization Synthesis 2005, 47-56
34. Nielsen, S. F.; Larsen, M.; Boesen, T.; Schonning, K; Kromann, H. Cationic Chalcone Antibiotics. Design, Synthesis, and Mechanism of Action J. Med. Chem. 2005, 48, 2667-2677
35. Bavetsias, V.; Sun, C.; Bouloc, N.; Reynisson, J.; Workman, P.; Linardopoulos, S.; McDonald, E. Hit Generation and Exploration: Imidazo[4,5- b ]pyridine Derivatives as Inhibitors of Aurora Kinases Bioorg. Med. Chem. Lett. 2007, 17, 6567-6571
36. Free, S. M., Jr.; Wilson, J. W. A Mathematical Contribution to Structure-Activity Studies J. Med. Chem. 1964, 7, 395-399
37. Milletti, F.; Storchi, L.; Sforna, G.; Cruciani, G. New and Original pKa Prediction Method Using Grid Molecular Interaction Fields J. Chem. Inf. Model. 2007, 47, 2172-2181
38. Zachariae, U.; Giordanetto, F.; Leach, A. G. Side Chain Flexibilities in the Human Ether-a-go-go Related Gene Potassium Channel (hERG) Together with Matched-Pair Binding Studies Suggest a New Binding Mode for Channel Blockers J. Med. Chem. 2009, 52, 4266-4276
39. Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups J. Med. Chem. 2006, 49, 5029-5046
40. Aronov, A. M. Ligand Structural Aspects of hERG Channel Blockade Curr. Top. Med. Chem. 2008, 8, 1113-1127
41. Waring, M. J.; Johnstone, C. A Quantitative Assessment of hERG Liability as a Function of Lipophilicity Bioorg. Med. Chem. Lett. 2007, 17, 1759-1764
42. Whitlock, G. A.; Blagg, J.; Fish, P. V. 1-(2-Phenoxypheny)methanamines: SAR for Dual Serotonin/Noradrenaline Reuptake Inhibition, Metabolic Stability and hERG Affinity Bioorg. Med. Chem. Lett. 2008, 18, 596-599
43. Van de Waterbeemd, H.; Smith, D. A.; Beaumont, K.; Walker, D. K. Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics J. Med. Chem. 2001, 44, 1313-1333
44. clogP was calculated using ChemBioDraw Ultra 12 by CambridgeSoft (www.cambridgesoft.com).
45. Kinase profiling using the KINOMEScan technology: www.kinomescan.com.
46. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors Nat. Biotechnol. 2005, 23, 329-336
47. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A Quantitative Analysis of Kinase Inhibitor Selectivity Nat. Biotechnol. 2008, 26, 127-132
48. + Acute Myeloid Leukaemia Resulting in Secondary D835Y Mutation: A Model for Emerging Clinical Resistance Patterns Leukemia 2012, 26, 1462-1470
49. Stirewalt, D. L.; Radich, J. P. The Role of FLT3 in Haematopoietic Malignancies Nat. Rev. Cancer 2003, 3, 650-665
50. Kindler, T.; Lipka, D. B.; Fischer, T. FLT3 as a Therapeutic Target in AML: Still Challenging After All These Years Blood 2010, 116, 5089-5102
51. Meshinchi, S.; Appelbaum, F. R. Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia Clin. Cancer Res. 2009, 15, 4263-4269
52. Meshinchi, S.; Alonzo, T. A.; Stirewalt, D. L.; Zwaan, M.; Zimmerman, M.; Reinhardt, D.; Kaspers, G. J. L.; Heerema, N. A.; Gerbing, R.; Lange, B. J.; Radich, J. P. Clinical Implications of FLT 3 Mutations in Pediatric AML Blood 2006, 108, 3654-3661
53. Levis, M. J. Will Newer Tyrosine Kinase Inhibitors Have an Impact in AML? Best Pract. Res. Clin. Haematol. 2010, 23, 489-494
54. Manfredi, M. G.; Ecsedy, J. A.; Meetze, K. A.; Balani, S. K.; Burenkova, O.; Chen, W.; Galvin, K. M.; Hoar, K. M.; Huck, J. J.; LeRoy, P. J.; Ray, E. T.; Sells, T. B.; Stringer, B.; Stroud, S. G.; Vos, T. J.; Weatherhead, G. S.; Wysong, D. R.; Zhang, M.; Bolen, J. B.; Claiborne, C. F. Antitumour Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora A kinase Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 4106-4111
55. Bouloc, N.; Large, J. M.; Kosmopoulou, M.; Sun, C.; Faisal, A.; Matteucci, M.; Reynisson, J.; Brown, N.; Atrash, B.; Blagg, J.; McDonald, E; Linardopoulos, S.; Bayliss, R.; Bavetsias, V. Structure-based Design of Imidazo[1,2- a ]pyrazine Derivatives as Selective Inhibitors of Aurora-A Kinase in Cells Bioorg. Med. Chem. Lett. 2010, 20, 5988-5993
56. Mizuki, M.; Fenski, R.; Halfter, H.; Matsumura, I.; Schmidt, R.; Muller, C.; Gruning, W.; Kratz-Albers, K.; Serve, S.; Steur, C.; Buchner, T.; Kienast, J.; Kanakura, Y.; Berdel, W. E.; Serve, H. Flt3 Mutations from Patients with Acute Myeloid Leukemia Induce Transformation of 32D Cells Mediated by Ras and STAT5 Pathways Blood 2000, 96, 3907-3914
57. Choudhary, C.; Brandts, C.; Schwable, J.; Tickenbrock, L.; Sargin, B.; Ueker, A.; Bohmer, F.-D.; Berdel, W. E.; Muller-Tidow, C.; Serve, H. Activation Mechanisms of STAT5 by Oncogenic Flt3-ITD Blood 2007, 110, 370-374
58. Moore, A.; Faisal, A.; Bavetsias, V.; Gonzalez de Castro, D.; Sun, C.; Atrash, B.; Valenti, M.; de Haven Brandon, A.; Avery, S.; Pearson, A.; Workman, P.; Blagg, J.; Raynaud, F.; Eccles, S.; Linardopoulos, S. The Dual FLT3-Aurora Inhibitor CCT241736 Overcomes Resistance to Selective FLT3 Inhibition Driven by FLT3 Ligand and FLT3 Point Mutations in Acute Myeloid Leukemia. Mol Cancer Ther, 2011, 10, Issue 11, Supplement 1, doi 10.1158/1535-7163.TARG-11-B74; Abstracts of AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Nov 12-16, 2011, San Francisco, CA.
59. Chan, F.; Sun, C.; Perumal, M.; Nguyen, Q.-D.; Bavetsias, V.; McDonald, E.; Martins, V.; Wilsher, N.; Valenti, M.; Eccles, S.; te Poele, R.; Workman, P.; Aboagye, E. O.; Linardopoulos, S. Mechanism of Action And in Vivo Quantification of Biological Activity of the Aurora Kinase Inhibitor CCT129202 Mol. Cancer Ther. 2007, 6, 3147-3157
60. CCP4 The CCP4 (Collaborative Computational Project Number 4) Suite: Programmes for Protein Crystallography Acta Crystallogr. Sect. D 1994, 50, 760-763
61. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: Building New Software for Automated Crystallographic Structure Determination Acta Crystallogr., Section D 2002, 58, 1948-1954
62. Moreno-Farre, J.; Workman, P.; Raynaud, F. I. Analysis of Potential Drug-Drug Interactions for Anticancer Agents in Human Liver Microsomes by High Throughput Liquid Chromatography/Mass Spectrometry Assay Aust.-Asian J. Cancer 2007, 6, 55-68
63. Ion Channel Cardiac Profiler; Millipore: Billerica, MA; http://www.millipore.com/life-sciences/flx4/ld-ion
64. hERG Safety Assay; Cyprotex plc, Cheshire, UK; www.cyprotex.com
65. Workman, P; Aboagye, E. O.; Balkwill, F.; Balmain, A.; Bruder, G.; Chaplin, D. J.; Double, J. A.; Everitt, J.; Farningham, D.; Glennie, M. J; Kelland, L. R.; Robinson, V.; Stratford, I. J.; Tozer, G. M.; Watson, S.; Wedge, S. R.; Eccles, S. A. Guidelines for the Welfare and Use of Animals in Cancer Research Br. J. Cancer 2010, 102, 1555-1577